PriceTargets.com logo

Cassava Sciences - SAVA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $111.50
  • Forecasted Upside: 3,150.73%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.43 As of 12/3/2024 01:03 PM ET
▼ -0.02 (-0.58%)

This chart shows the closing price for SAVA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cassava Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAVA

Analyst Price Target is $111.50
▲ +3,150.73% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Cassava Sciences in the last 3 months. The average price target is $111.50, with a high forecast of $116.00 and a low forecast of $107.00. The average price target represents a 3,150.73% upside from the last price of $3.43.

This chart shows the closing price for SAVA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Cassava Sciences. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/26/2024HC WainwrightDowngradeBuy ➝ Neutral$116.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$116.00 ➝ $116.00
10/8/2024HC WainwrightUpgradeNeutral ➝ Buy$116.00
8/13/2024HC WainwrightReiterated RatingNeutral
8/8/2024Rodman & RenshawReiterated RatingBuy ➝ Buy$107.00 ➝ $107.00
7/19/2024HC WainwrightReiterated RatingNeutral
7/1/2024HC WainwrightDowngradeBuy ➝ Neutral
5/17/2024HC WainwrightBoost TargetBuy ➝ Buy$124.00 ➝ $131.00
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$124.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$88.57
3/6/2023HC WainwrightReiterated RatingBuy$88.57
1/25/2023B. RileyLower Target$31.43 ➝ $20.00
1/24/2023HC WainwrightReiterated RatingBuy$88.57
11/29/2022Univest SecLower Target$8.57 ➝ $7.86
11/16/2022B. RileyDowngradeBuy ➝ Neutral$31.43
11/8/2022Univest SecBoost TargetSell ➝ Sell$5.71 ➝ $8.57
8/11/2022B. RileyLower TargetBuy$41.43 ➝ $31.43
8/4/2022HC WainwrightReiterated RatingBuy
5/6/2022B. RileyLower Target$51.43 ➝ $41.43
5/5/2022B. RileyReiterated RatingBuy
4/4/2022Univest SecInitiated CoverageSell
1/24/2022B. RileyLower TargetBuy$77.14 ➝ $51.43
9/3/2021JonestradingReiterated RatingBuy$153.57
8/25/2021JonestradingReiterated RatingBuy$153.57
8/3/2021B. RileyBoost TargetBuy$79.29 ➝ $103.57
7/20/2021HC WainwrightBoost TargetPositive ➝ Buy$69.29 ➝ $88.57
7/15/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral$71.43
6/23/2021B. RileyBoost TargetBuy$55.71 ➝ $79.29
4/27/2021B. RileyInitiated CoverageBuy$55.71
3/23/2021JonestradingReiterated RatingBuy
3/17/2021JonestradingInitiated CoverageBuy
3/16/2021Cantor FitzgeraldBoost TargetOverweight$17.14 ➝ $51.43
10/22/2020Cantor FitzgeraldInitiated CoverageOverweight$17.14
9/23/2020HC WainwrightUpgradeNeutral ➝ Buy$14.29
9/14/2020Maxim GroupUpgradeHold ➝ Buy$10.00
6/7/2020Maxim GroupReiterated RatingHold
5/18/2020HC WainwrightDowngradeBuy ➝ Neutral
5/15/2020Maxim GroupDowngradeBuy ➝ Hold
5/8/2020HC WainwrightReiterated RatingBuy$4.29 ➝ $11.43
3/26/2020Maxim GroupInitiated CoverageBuy$8.57
1/10/2020Maxim GroupBoost TargetBuy$2.14 ➝ $8.57
12/6/2019HC WainwrightReiterated RatingPositive ➝ Buy$2.14 ➝ $4.29
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 7 very positive mentions
  • 17 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 3 very positive mentions
  • 26 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 2 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
10/4/2024
  • 3 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/3/2024
  • 4 very positive mentions
  • 28 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 4 very positive mentions
  • 28 positive mentions
  • 8 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cassava Sciences logo
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Read More

Today's Range

Now: $3.43
Low: $3.25
High: $3.52

50 Day Range

MA: $24.48
Low: $3.45
High: $32.06

52 Week Range

Now: $3.43
Low: $3.25
High: $42.20

Volume

4,884,831 shs

Average Volume

2,480,528 shs

Market Capitalization

$165.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cassava Sciences?

The following Wall Street analysts have issued research reports on Cassava Sciences in the last year: HC Wainwright, and Rodman & Renshaw.
View the latest analyst ratings for SAVA.

What is the current price target for Cassava Sciences?

0 Wall Street analysts have set twelve-month price targets for Cassava Sciences in the last year. Their average twelve-month price target is $111.50, suggesting a possible upside of 3,248.3%. HC Wainwright has the highest price target set, predicting SAVA will reach $116.00 in the next twelve months. Rodman & Renshaw has the lowest price target set, forecasting a price of $107.00 for Cassava Sciences in the next year.
View the latest price targets for SAVA.

What is the current consensus analyst rating for Cassava Sciences?

Cassava Sciences currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SAVA.

What other companies compete with Cassava Sciences?

Other companies that are similar to Cassava Sciences include Tourmaline Bio, Taysha Gene Therapies, Stoke Therapeutics, Exscientia and Monte Rosa Therapeutics. Learn More about companies similar to Cassava Sciences.

How do I contact Cassava Sciences' investor relations team?

Cassava Sciences' physical mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company's listed phone number is (512) 501-2444 and its investor relations email address is [email protected]. The official website for Cassava Sciences is www.cassavasciences.com. Learn More about contacing Cassava Sciences investor relations.